Type 2 immunity is protective in metabolic disease but exacerbates NAFLD collaboratively with TGF-β

• Published in: Science translational medicine 2017-06, Vol.9 (396)
• Main Authors: Hart, Kevin M, Fabre, Thomas, Sciurba, Joshua C, Gieseck, 3rd, Richard L, Borthwick, Lee A, Vannella, Kevin M, Acciani, Thomas H, de Queiroz Prado, Rafael, Thompson, Robert W, White, Sandra, Soucy, Genevieve, Bilodeau, Marc, Ramalingam, Thirumalai R, Arron, Joseph R, Shoukry, Naglaa H, Wynn, Thomas A
• Format: Article
• Language: English
• Subjects: Adipose Tissue - pathology; Animals; Diet, High-Fat; Disease Progression; Eosinophils - pathology; Humans; Immunity; Inflammation - pathology; Interferon-gamma - deficiency; Interferon-gamma - metabolism; Liver Cirrhosis - pathology; Male; Metabolic Diseases - immunology; Metabolic Diseases - prevention & control; Mice, Inbred C57BL; Non-alcoholic Fatty Liver Disease - immunology; Non-alcoholic Fatty Liver Disease - pathology; Non-alcoholic Fatty Liver Disease - prevention & control; Obesity - pathology; Transforming Growth Factor beta - metabolism
• ISSN: 1946-6234; 1946-6242
• DOI: 10.1126/scitranslmed.aal3694

Nonalcoholic fatty liver disease (NAFLD) is now the most common progressive liver disease in developed countries and is the second leading indication for liver transplantation due to the extensive fibrosis it causes. NAFLD progression is thought to be tied to chronic low-level type 1 inflammation originating in the adipose tissue during obesity; however, the specific immunological mechanisms regulating the progression of NAFLD-associated fibrosis in the liver are unclear. To investigate the immunopathogenesis of NAFLD more completely, we investigated adipose dysfunction, nonalcoholic steatohepatitis (NASH), and fibrosis in mice that develop polarized type 1 or type 2 immune responses. Unexpectedly, obese interleukin-10 (IL-10)/IL-4-deficient mice (type 1-polarized) were highly resistant to NASH. This protection was associated with an increased hepatic interferon-γ (IFN-γ) signature. Conversely, IFN-γ-deficient mice progressed rapidly to NASH with evidence of fibrosis dependent on transforming growth factor-β (TGF-β) and IL-13 signaling. Unlike increasing type 1 inflammation and the marked loss of eosinophils seen in expanding adipose tissue, progression of NASH was associated with increasing eosinophilic type 2 liver inflammation in mice and human patient biopsies. Finally, simultaneous inhibition of TGF-β and IL-13 signaling attenuated the fibrotic machinery more completely than TGF-β alone in NAFLD-associated fibrosis. Thus, although type 2 immunity maintains healthy metabolic signaling in adipose tissues, it exacerbates the progression of NAFLD collaboratively with TGF-β in the liver.